Collins Medical Trust Report issue

Foundation Phase 2 Phase 4

Organization Overview

First Clinical Trial
2009
NCT00962429
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Collins Medical Trust

Active Ingredients

Drugs in Phase 4 Trials (1)

iron dextran (INFeD) (1 trial)

Drugs in Phase 2 Trials (1)

alpha-lipoic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Polyneuropathies (Phase 2)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2